Zobrazeno 1 - 4
of 4
pro vyhledávání: '"T L, Dunleavy"'
Autor:
F R, Dunphy, T L, Dunleavy, B R, Harrison, K M, Trinkaus, H J, Kim, B C, Stack, B, Needles, J H, Boyd
Publikováno v:
Cancer. 91(5)
After standard therapy for advanced head and neck carcinoma, 5-year survival rate is less than 50%. Our purpose was to develop a new treatment for advanced head and neck carcinoma by using preoperative chemotherapy. Long term efficacy and toxicity of
Publikováno v:
Cancer. 86(7)
Anemia has been reported to develop during preoperative chemotherapy with paclitaxel and carboplatin. The use of recombinant human erythropoietin (EPO) has been shown to reduce anemia and subsequent packed red blood cell transfusions. The current stu
Autor:
F R, Dunphy, J H, Boyd, H J, Kim, C H, Dunphy, B R, Harrison, T L, Dunleavy, J J, Rodriguez, E M, McDonough, J R, Minster, J G, Hilton
Publikováno v:
Cancer. 79(10)
Standard therapy for advanced head and neck carcinoma is surgery and radiation, and the subsequent 5-year survival with this treatment has been less than 50%. New combined modality treatment strategies are being tested to improve survival. New chemot
Autor:
F R, Dunphy, T L, Dunleavy, B R, Harrison, J H, Boyd, M A, Varvares, C H, Dunphy, J J, Rodriguez, E M, McDonough, J R, Minster, M D, McGrady
Publikováno v:
Cancer. 79(8)
The authors report on anemia observed during preoperative paclitaxel and carboplatin chemotherapy in patients with advanced head and neck carcinoma and discuss how the use of recombinant human erythropoietin (r-HuEPO) ameliorates this anemia, reducin